Q & A: Kenneth Tanabe works to solve the mysteries of liver cancer: While progress has been relatively slow, this noted expert sees reasons for hope

摘要

Kenneth Kenji Tanabe, MD, is Chief of the Division of Surgical Oncology at the Massachusetts General Hospital (MGH), Deputy Clinical Director of the MGH Cancer Center, director of the MGH Liver Surgery Program, and a Professor of Surgery at Harvard Medical School. His clinical practice focuses on surgical management of patients with liver tumors and patients with melanoma, and he is a member of the melanoma committee of the National Comprehensive Cancer Network. His research laboratory, which has been continuously funded by the National Institutes of Health since 1993, focuses on prevention of hepatocellular carcinoma (HCC) and experimental gene therapy for liver tumors. He is the author or coauthor of more than 100 peer-reviewed scientific articles and 50 review articles and book chapters on melanoma and liver cancer. He received his medical degree from the University of California at San Diego and completed a residency at the Cornell University Medical Center and a fellowship atMD Anderson Hospital and Tumor Institute.